ProfileGDS5678 / 1429008_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 85% 83% 83% 84% 83% 84% 77% 83% 81% 86% 84% 86% 84% 85% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.3891485
GSM967853U87-EV human glioblastoma xenograft - Control 26.1192983
GSM967854U87-EV human glioblastoma xenograft - Control 36.1273483
GSM967855U87-EV human glioblastoma xenograft - Control 46.3524484
GSM967856U87-EV human glioblastoma xenograft - Control 56.1694783
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.0475684
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.1718577
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.0847583
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.7317281
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.541486
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.2613984
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.5018686
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.2080384
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.2673585